Leading The Way In Pediatric Endo-Cannabinoid Medicine

Phyto Therapeutic Medicine for Inflammatory Conditions

Initial 2.2 Million Square Feet of Cultivation

Exclusive Clinically Validated Formulations

Innovation in Skin Care and Anti-Aging Systems

Relevium Announces Record Sales From the Bioganix® Brand and Provides CBD Update

MONTREAL, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company hit a record high in monthly sales in the month of July 2019 for its...

Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

MONTREAL, July 10, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which...

Relevium’s CEO Issues Letter of Clarification to Shareholders

MONTREAL, July 03, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today a letter from Aurelio Useche, CEO to shareholders to clarify misconceptions and rumours in the...

Relevium Technologies

Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.

Subscribe to our Newsletter

You have Successfully Subscribed!